dc.contributor.author |
Eckardt, Julia |
|
dc.contributor.author |
Schroeder, Christopher |
|
dc.contributor.author |
Martus, Peter |
|
dc.contributor.author |
Armeanu-Ebinger, Sorin |
|
dc.contributor.author |
Kelemen, Olga |
|
dc.contributor.author |
Gschwind, Axel |
|
dc.contributor.author |
Bonzheim, Irina |
|
dc.contributor.author |
Amaral, Teresa |
|
dc.contributor.author |
Ossowski, Stephan |
|
dc.contributor.author |
Rieß, Olaf |
|
dc.contributor.author |
Flatz, Lukas |
|
dc.contributor.author |
Garbe, Claus |
|
dc.contributor.author |
Forschner, Andrea Lydia |
|
dc.date.accessioned |
2023-10-31T09:54:08Z |
|
dc.date.available |
2023-10-31T09:54:08Z |
|
dc.date.issued |
2023 |
|
dc.identifier.issn |
0171-5216 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/146993 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Springer |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1007/s00432-022-03939-w |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20230619000000_02161 |
|
utue.publikation.seiten |
833-840 |
de_DE |
utue.personen.roh |
Eckardt, Julia |
|
utue.personen.roh |
Schroeder, Christopher |
|
utue.personen.roh |
Martus, Peter |
|
utue.personen.roh |
Armeanu-Ebinger, Sorin |
|
utue.personen.roh |
Kelemen, Olga |
|
utue.personen.roh |
Gschwind, Axel |
|
utue.personen.roh |
Bonzheim, Irina |
|
utue.personen.roh |
Eigentler, Thomas |
|
utue.personen.roh |
Amaral, Teresa |
|
utue.personen.roh |
Ossowski, Stephan |
|
utue.personen.roh |
Riess, Olaf |
|
utue.personen.roh |
Flatz, Lukas |
|
utue.personen.roh |
Garbe, Claus |
|
utue.personen.roh |
Forschner, Andrea |
|
dcterms.isPartOf.ZSTitelID |
Journal of Cancer Research and Clinical Oncology |
de_DE |
dcterms.isPartOf.ZS-Issue |
2 |
de_DE |
dcterms.isPartOf.ZS-Volume |
149 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |